Safety and Efficacy of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem from a Phase 2, Randomized Clinical Trial in Pediatric Participants with Complicated Intra-abdominal Infection

Carl Christian A. Jackson, Jason Newland, Nataliia Dementieva, Julia Lonchar, Feng Hsiu Su, Jennifer A. Huntington, Mekki Bensaci, Myra W. Popejoy, Matthew G. Johnson, Carisa De Anda, Elizabeth G. Rhee, Christopher J. Bruno

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Background: Ceftolozane/tazobactam, a cephalosporin-β-lactamase inhibitor combination, is approved for the treatment of complicated urinary tract infections and complicated intra-abdominal infections (cIAI). The safety and efficacy of ceftolozane/tazobactam in pediatric participants with cIAI were assessed. Methods: This phase 2 study (NCT03217136) randomized participants to either ceftolozane/tazobactam+metronidazole or meropenem for treatment of cIAI in pediatric participants (<18 years). The primary objective was to assess the safety and tolerability of intravenous ceftolozane/tazobactam+metronidazole. Clinical cure at end of treatment (EOT) and test of cure (TOC) visits were secondary end points. Results: The modified intent-to-treat (MITT) population included 91 participants (ceftolozane/tazobactam+metronidazole, n = 70; meropenem, n = 21). Complicated appendicitis was the most common diagnosis (93.4%); Escherichia coli was the most common pathogen (65.9%). Adverse events (AEs) occurred in 80.0% and 61.9% of participants receiving ceftolozane/tazobactam+metronidazole and meropenem, drug-related AEs occurred in 18.6% and 14.3% and serious AEs occurred in 11.4% and 0% of participants receiving ceftolozane/tazobactam+metronidazole and meropenem, respectively. No drug-related serious AEs or discontinuations due to drug-related AEs occurred. Rates of the clinical cure for ceftolozane/tazobactam+metronidazole and meropenem at EOT were 80.0% and 95.2% (difference: -14.3; 95% confidence interval: -26.67 to 4.93) and at TOC were 80.0% and 100.0% (difference: -19.1; 95% confidence interval: -30.18 to -2.89), respectively; 6 of the 14 clinical failures for ceftolozane/tazobactam+metronidazole at TOC were indeterminate responses imputed as failures per protocol. Conclusion: Ceftolozane/tazobactam+metronidazole was well tolerated in pediatric participants with cIAI and had a safety profile similar to the established safety profile in adults. In this descriptive efficacy analysis, ceftolozane/tazobactam+metronidazole appeared efficacious.

Original languageEnglish
Pages (from-to)557-563
Number of pages7
JournalPediatric Infectious Disease Journal
Volume42
Issue number7
DOIs
StatePublished - Jul 2023

Keywords

  • Enterobacterales
  • Gram-negative
  • adolescent
  • cIAI
  • children

Fingerprint

Dive into the research topics of 'Safety and Efficacy of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem from a Phase 2, Randomized Clinical Trial in Pediatric Participants with Complicated Intra-abdominal Infection'. Together they form a unique fingerprint.

Cite this